Alnylam Pharmaceuticals (DUL.DE) Stock Analysis & Winston Score

Alnylam Pharmaceuticals is a biotech company that makes medicines for rare, serious diseases caused by faulty genes. Its drugs work by "silencing" specific genes that cause illness — a technology called RNA interference, or RNAi. Its main approved products include Onpattro, Givlaari, Oxlumo, and Leqvio, which treat conditions like a nerve disease called hATTR amyloidosis and a liver disorder called acute hepatic porphyria. The company earns money by selling these specialty drugs directly and through partnerships with larger pharmaceutical companies, including Novartis, which helps commercialize Leqvio globally. Alnylam operates mainly in the United States and Europe and generates roughly $2–3 billion in annual revenue. Its core advantage is its pioneering position in RNAi technology, which took decades to develop and is difficult for competitors to replicate quickly. The key growth driver is expanding its pipeline of RNAi medicines into more common diseases, though the main risk is the high cost and uncertainty of drug development and regulatory approval.